Statistics

Total Visits

Views
GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutati13

Select a period of time:

Number of views in the range

Views
GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutati6

Views

Views
April 20240
May 20243
June 20241
July 20241
August 20241
September 20240
October 20240
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States6
 

Top cities views

Views
Chicago2
Fort Worth1